Sun Pharmaceutical Industries’ shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in women’s health. This strategic move aims to bolster Sun Pharma’s innovative medicines business and establish it as a top-tier player in biosimilars and women’s health globally.
Recent Posts
- A long-time developer wants to split Bitcoin blockchain and reassign Satoshi coins. The community is calling it a theft
- Pudgy Penguins, BAYC rally masks a shrinking NFT market as volumes and users fall
- Iran reportedly proposes Hormuz Strait deal to U.S. Here’s where things stand — and what’s next for markets
- Acko lines up ICICI Sec, Kotak, Morgan Stanley for $2 billion IPO
- Varun Beverages Q4 results: Net profit jumps 20% at ₹872.3 crore YoY, revenue up 18.3%; ₹0.50 dividend declared